Top

Published in:

01-02-2021 | NSCLC | Clinical study

Risk of PD-1- and PD-L1-inhibitor-related pneumonia

Published in: Reactions Weekly | Issue 1/2021

Excerpt

Programmed cell death-1 (PD-1) and programmed cell death ligand-1(PD-L1) inhibitor therapy increases the risk of pneumonia in patients with non-small cell lung cancer (NSCLC), according to findings of a systematic review and meta-analysis published in the European Journal of Clinical Pharmacology. …

Tong ZQ, et al. Incidence risk of PD-1/PD-L1-related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology : 10 Feb 2021. Available from: URL: http://doi.org/10.1007/s00228-020-03083-9

Title: Risk of PD-1- and PD-L1-inhibitor-related pneumonia
Publication date: 01-02-2021
Publisher: Springer International Publishing
Keywords: NSCLC
NSCLC
Pneumonia
Diarrhea
Diarrhea
Published in: Reactions Weekly / Issue 1/2021
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-021-91111-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Risk of PD-1- and PD-L1-inhibitor-related pneumonia

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

Ciprofloxacin

Raloxifene

Multiple drugs

Multiple drugs

Hyaluronic acid/lidocaine

Cisplatin/unspecified antineoplastics